ASYMPTOMATIC APLASTIC ANAEMIA IN A PATIENT RECEIVING ANTI-TUBERCULOSIS TREATMENT

Transcription

ASYMPTOMATIC APLASTIC ANAEMIA IN A PATIENT RECEIVING ANTI-TUBERCULOSIS TREATMENT
Case Report
Ind. J Tub., 2001, 48, 97
ASYMPTOMATIC APLASTIC ANAEMIA IN A PATIENT RECEIVING
ANTI-TUBERCULOSIS TREATMENT
Anil K. Agarwal, Inder Mohan Chugh, Chandramani Punjabi, Sumita Dewan* and Ashok Shah
(Received on 25.9.2000, Revised Version received on 15.2.2001, Accepted on 22.2.2001)
Summary: Blood dyscrasias with anti-tuberculosis drugs are known but rarely encountered and even less thought of. We
describe a patient who developed pancytopenia due to aplastic anaemia of moderate severity which was diagnosed after
7 months of therapy. This was thought to be an idiosyncratic response to Streptomycin. A 6 month clinical follow-up after
cessation of therapy revealed that the blood counts continued to remain depressed, but she was totally asymptomatic.
Subsequently, we were informed that the patient had an uncomplicated normal vaginal delivery 2 years after stopping
therapy.
INTRODUCTION
Blood dyscrasias induced by anti-tuberculosis
drugs are known but are rarely encountered. A wide
range of haematological abnormalities has been
reported with these drugs. However, the physician
rarely suspects this serious complication which can
have fatal consequences. Aplastic anaemia is a
hyporegenerative bone marrow disorder characterised
pathologically by a reduction in the amount of
haemopocitic bone marrow and pancytopenia1. Drugs
are often indicted as a major cause of acquired aplastic
anaemia. We describe a patient who developed
pancytopenia due to aplaslic anaemia of moderate
severity while receiving anti-tuberculosis therapy,
probably caused by an idiosyncratic reaction to
Streptomycin. Although her total leucocytic and
platelet counts were still depressed 6 months after
cessation of drugs, the patient was asymptomatic.
This case report was prompted by the rarity of such
reports in the literature.
CASE REPORT
A 25-year-old female was referred to our
Institute for re-evaluation of anti-tuberculosis therapy
(ATT) initiated 3 months before presentation. Five
months prior to referral, she had developed high grade
continuous fever of acute onset for which she
consulted a general practitioner. She was administered
various courses of antibiotics and symptomatic
treatment but with no relief. A borderline positive
Widal test resulted in suspicion of typhoid fever for
which she received a course of Ofloxacin but without
relief. The patient did not receive Chloramphenicol.
Two months later, she experienced loss of appetite
along with generalised weakness and was then
admitted in a nursing home. A chest roentgenogram
showed right side plcural effusion which was
confirmed on computed tomography (CT) of thorax.
The CT also revealed enlarged right hilar and carinal
lymph nodes. Based on her radiological profile, she
was diagnosed as a case of pulmonary tuberculosis
with pleural effusion and was started on an antituberculosis regimen comprising Rifampicin 450 mg,
Isoniazid 300 mg, Pyrazinamide 1500 mg and
Ethambutol 800 mg once daily. Ten days after
initiation of ATT, she developed jaundice and her
liver function tests were deranged. Rifampicin and
Pyraziaamide were stopped and Streptomycin
0.75g once daily intramuscularly was added to
Isoniazid and Ethambutol. Oral Prednisolone was
also added which was gradually tapered off. However,
pleural tap was not done. Six weeks subsequent to
rescheduling of the ATT, she felt better and her
symptoms gradually disappeared. She was still on
the three drugs (Streptomycin, Isoniazid and
Ethambutol) when she reported to us.
Physical examination revealed a pale young
female of average built in no acute distress. There
was no clubbing, cyanosis or any significant
lymphadenopathy. Diaphragmatic excursion was
decreased on the right side. Percussion note was dull
Department ot Respiratory Medicine, Vallabhbhai Patel Chest Institute, University of Delhi. Delhi and *Haematologist, Department ot Medicine.
Safdarjung Hospital, New Delhi
Correspondence :Dr. Ashok Shah M.D., Department of Respiratory Medicine. Vallahhbhai Patel Chest Institute. University oi Delhi. P.O. Box 2101.
Delhi-110007
98
ANIL K. AGARWAL ET AL
and 202 KAU/dL respectively. The liver function
on the right infrascapular and infraaxillary regions tests were within normal limits when she reported to
Breath sounds were decreased in the same areas with us and it continued to remain so. Other investigations
no adventitious sounds. No other abnormality was which included serum proteins, serum calcium blood
detected.
sugar, stool examination, etc. did not show any
abnormality. Tuberculin test with 1 TU did not show
LABORATORY INVESTIGATIONS
any induration. Tests for human immunodeficiency
virus (HIV) were also negative. Repeated direct
Haematological investigations, done on
smear stains for acid fast bacilli were also negative
presentation, showed haemoglobin 9.2 g/dL with
and the culture did not grow Mycobacterium
total leucocyte count 4000/mm’ and differential
leucocyte count: 82% neutrophils, 16% lymphocytes tuberculosis.
and 2% eosinophils. The platelet count was 3,49,0007
CLINICAL COURSE
mm1 and peripheral blood smear showed neutrophilia
along With anisocytosis and microcytosis. Her urine
The patient improved clinically with ATT and
examination was within normal limits. A review of
her symptoms gradually disappeared. Prednisolone
her haemogram over the preceding 5 months (Table
was tapered off and stopped 2 weeks after presenting
1) revealed that at the time of initiation of ATT her
to us. Anti-tuberculosis therapy comprising
1
total leucocyte count was 6150/mm and haemoglobin
Streptomycin, Isoniazid and Ethambutol was
was 5.4 g/dL for which she received 3 units of blood
continued. Rifampicin and Pyrazinamide were
transition which raised the haemoglobin level. Liver
introduced 6 weeks later and Streptomycin was
function tests done when she developed jaundice
withdrawn 3 weeks later(Figure 1). A chest
showed serum bilirubin of 3.21 mg/dL with SCOT,
roentgenogram done at the time of presentation had
SGPT and alkaline phosphatase 115 IU/L, 135 ITj/L
shown minimal right side pleural effusion, confirmed
on ultrasonography, which subsequently disappeared.
Haemogram done at the end of the seventh
month of therapy showed a sharp decline in the total
leucocyte and platelet counts. ATT was stopped
forthwith. A bone marrow aspiration (Figure 2)
revealed moderately hypocellular marrow with severe
megaloblastic changes. There were no ring
sideroblasts in the bone marrow. A chest
roentgenogram as well as CT thorax done after
stopping ATT were read as normal. The patient
remained asymptomatic but her total leucocyte and
platelet counts continued to remain depressed even
6 months after cessation of ATT with no untoward
effects. Although the patient was lost to clinical follow
up after 6 months, yet we were informed that she
had an uncomplicated normal vaginal delivery 2 years
after stopping therapy.
DISCUSSION
Blood dyscrasias comprise 10% of the total
number of drug induced adverse effects and account
tor approximately 40% of fatal reactions related to
drug administration2. Although blood dyscrasias are
known to occur with ATT, the adverse effect is not
a 25-year-old female,
APLASTIC ANAEMIA DURING ANTI-TUBERCULOSIS TREATMENT
99
Table 1: Showing duration and combination of anti-tuberculosis therapy along with haemotological profile
17/3/97 25/3/97 5/4/97 15/4/97
Hb
24/5/97 12/6/97 14/10/97
20/10/97 9/12/97 20/1/98 11/4/98
5.4 6.3
9.9
10.3
8.7
9.2
10.2
10.7
TLC
6150 6200
7050
15300
9450
4000
1800
2000
DLC
P73L20 P70L28
P62L35
P83L14
P75L24
P82L16 P69L26
- P73L23
P87L1 1
EOM2
EOM3
E2M1
E1MO
E2MO
E4M1
-
E3M 1
E2M2
PCV
22%
-
-
-
28.4%
29.4%
-
28.8%
3.3%
ESR
-
-
90
120
-
35
49
Platelets
-
-
-
-
349
116
110
12.1
3100
10.1
2400
11.8
3490
55
-
194
186
Hb : hameoglobin, P: polymorphonuclear cells, L: lymphocytes, E:eosinophils, M : monocytes
to aplastic anaemia. Although the total leucocyte
An idiosyncratic response to a drug is not dose
count (TLC) had fallen to 4000/cu.mm after 3 related. Although it can be seen with the first dose,
months of Streptomycin, Isoniazid and Ethambutol, it seems to occur when patient is exposed to the drug
the platelet count was still normal. However, a sharp on more than one occasion and during prolonged
decline in both the parameters was observed after 7 therapy4. The symptoms may sometimes not manifest
months of ATT, by which time Streptomycin was for weeks or months. There is currently no evidence
withdrawn and Rifampicin and Pyrazinamide added to account for a mechanism regarding the
for 12 weeks. Standard text books1-3 state that the idiosyncratic response to any drug1. This makes it
peripheral blood counts usually return to normal after difficult to investigate adverse drug reactions
withdrawal of the offending drug but, in our case, ascribed to idiosyncracy2.
the counts remained depressed even 6 months after
cessation of therapy, and the patient remained
Aplastic anaemia is an uncommon occurrence
asymptomatic. This led us to think that it may have with ATT. In a study of 108 patients with aplastic
been caused by an idiosyncratic reaction to
anaemia, only three (2.8%) were found to be taking
Figure
2: Bone marrow aspiration showing
hypocellular marrow fragments and a few
haemopoeitic cells (Leishmen’s stain x 40)
Streptomycin, since this drug has been incriminated
earlier.
ATT2. Williams et aP reported three cases of aplastic
anaemia occurring in association with ATT. All the
three patients died of haemorrhage secondary to
thrombocytopenia, consistent with an irreversible
damage of the bone marrow. The patients were on
different combinations of Streptomycin,
Thioacetazone, Isoniazid, Para-aminosalicylic acid
and Dimethylcarbazine. Deyke and Wallace’1,
reported two cases of aplastic anaemia when using
Streptomycin injections alone, on the 79th and 95*
days of treatment. Of the two patients, one died 19
days after detection while for the other patient, the
recovery was doubtful. Our patient, however,
underwent an uneventful pregnancy, with a successful
outcome, 24 months after cessation of ATT. An earlier
review7 had incriminated Para-aminosalicylic acid
and Streptomycin as causative agents for aplastic
anaemia. We presume that the idiosyncratic reaction,
in our patient, was due to Streptomycin even though
he had also Isoniazid and Ethambutol. Although
100
ANII, K. AGARWAL KT AL
aplastic anaemia due to Streptomycin alone6 and ACKNOWLEDGEMENT
Isoniazid in combination with other drugs2’”1 has been
The authors are grateful to Dr. Desh Deepak
documented, Isoniazid as the sole cause of aplastic
for
composing
Figure 1 and Table I.
anaemia is yet to be reported. The possibility of
Ethambutol being the offending agent also remains
open, but to OUR knowledge, there are no reports in REFERENCES
the literature implicating Ethambutol as a cause of
1. Firkin F, Chesterman C, Penington D, Rush B, (eds) De
aplastic anaemia.
Blood dyscrasias,, as a complication of
tuberculosis, are also known8. Pancytopenia is most
commonly associated with the disseminated forms
of the disease but is best known to occur with miliary
tuberculosis7. Pancytopenia due to hemophagocytic
syndrome as a presentation of tuberculosis has also
been recordedy. This syndrome is characterized by
fever, hepatosplenomegaly, pancytopenia and
proliferation of histiocytes with erythrophagocytosis,
and is thought to be due to immune dysregulation
secondary to tuberculosis.
It is estimated that annually over 8 million people
develop active tuberculosis and aproximately 2.9
million patients die of the disease10. Considering the
number of patients who are taking ATT at any
particular time and the number of patients who are
initiated on ATT in a year, there remains an immense
potential for the occurrence of blood dyscrasias. The
physicians should remain alert to the fact that these
may be caused by the disease itself or with drugs
when on ATT. Early detection of blood dyscrasias
along with early intervention could hopefully lead to
reduction in morbidity and mortality.
Gruchy’s Clinical Haematology in Medical Practice: 5”‘
ed.; Delhi: Oxford University Press; 1989; I 19
2. Holdiness MR. A review of blood dyscrasias induced by
the anti-tuberculosis drugs. Tubercle 1987; 68:301
3. Williams DM. Pancytopenia, aplastic anemia, and pure
red cell aplasia. In: Lee GR, Bithell TC, Foerster J. Athens
JW, Lukens JN, (eds). Wintrobe’s Clinical Hematology;
9’” cd; Vol.1. Philadelphia: Lea & Febiger; 1993; 913
4. Klaassen CD. Principles of toxicology and treatment of
poisoning. In Hardman JG. Oilman AG, Limbird LE, (ed)
Goodman and Oilman’s The pharmacological basis of
therapeutics. 9”‘ ed. New York: McGraw-Hill; 1996; 63
5. Williams CKO. Aderoju EA. Adenle AD, Sekoni G. Esan
GJF. Aplastic anaemia associated with anti-tuberculosis
chemotherapy. Ada Hoc-mat 1982; 68:329
6. Deyke VF, Wallace JB. Development of aplastic anemia
during the use of streptomycin. JAMA 1948; 136:1098
7. Cameron SJ. Tuberculosis and the blood - A special
relationship? Tubercle 1974; 55:55
8. Goldenberg AS. Hematologjc abnormalities and
mycobacterial infections. In Rom WN, Garay SM,(ed)
Tuberculosis. Boston: Little, Brown and Company; 1996;
645
9. Basu S, Mohan H, Malhotra H. Pancytopenia due to
hemophagocytic syndrome as the presenting manifestation
of tuberculosis. JAP! 2000; 48: 845
10. Malm AS, McAdam KPWJ. Escalating threat from
tuberculosis: The third epidemic. Thorax 1995; 5()(Suppl
I):S37